List of investigational hallucinogens and entactogens


This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved.
Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The list also includes non-hallucinogenic drugs related to hallucinogens, such as non-hallucinogenic serotonin 5-HT2A receptor agonists and non-hallucinogenic ketamine analogues. Cannabinoids, or cannabinoid receptor modulators, are not included in this list. Many of the indications are not for continuous medication therapy but rather are for medication-assisted psychotherapy or short-term use only. The section that the drug is in corresponds to its highest developmental phase, not its phase for all listed indications.
This list was last comprehensively updated in October 2024. It is likely to become outdated with time.

Under development

Preregistration

  • Midomafetamine – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen – post-traumatic stress disorder, alcoholism, social anxiety in autism – Multidisciplinary Association for Psychedelic Studies, Lykos Therapeutics

    Phase 3

  • CYB003 – serotonin 5-HT2A receptor agonist and psychedelic hallucinogen – major depressive disorder, alcoholism, psychiatric disorders – Cybin
  • Ketamine – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – alcoholism, binge-eating disorder, gambling, impulse control disorders, obsessive–compulsive disorder – Awakn Life Sciences
  • Ketamine – ionotropic glutamate NMDA receptor antagonist – suicidal ideation, mental disorders – NRx Pharmaceuticals
  • Lysergic acid diethylamide – non-selective serotonin receptor agonist and psychedelic hallucinogen – anxiety disorders, attention-deficit hyperactivity disorder, cluster headache, major depressive disorder, pain – MindMed
  • Lysergic acid diethylamide – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder, existential distress in cancer patients – MindBio Therapeutics
  • Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders, anorexia nervosa, bipolar depression, major depressive disorder, post-traumatic stress disorder, somatoform disorders, pervasive child development disorders – COMPASS Pathways
  • Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder, borderline personality disorder – Usona Institute

    Phase 2

  • Arketamine – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – depressive disorders – ATAI Life Sciences
  • Blixeprodil -4-fluorodeschloroketamine; – orally active NMDA receptor receptor antagonist – major depressive disorder, bipolar depression, depressive disorders – Gilgamesh Pharmaceuticals
  • Bretisilocin – serotonin 5-HT2A and 5-HT2C receptor agonist, serotonin 5-HT2B receptor antagonist, psychedelic hallucinogen, and serotonin releasing agent – major depressive disorder – Gilgamesh Pharmaceuticals
  • CYB004 – non-selective serotonin receptor agonist and psychedelic hallucinogen – generalized anxiety disorder – Cybin
  • Dimethyltryptamine – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders, fibromyalgia, substance-related disorders – Biomind Labs
  • Esketamine – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – major depressive disorder, bipolar depression – Clexio Biosciences
  • Ketamine – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – post-traumatic stress disorder, suicidal ideation, acute pain, cancer pain – Seelos Therapeutics
  • Ketamine extended-release – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – major depressive disorder – Douglas Pharmaceuticals
  • Ketamine prolonged-release oral – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – depressive disorders, neuropathic pain – Ketabon
  • Ketamine/temsirolimus – ionotropic glutamate NMDA receptor antagonist, dissociative hallucinogen, and mTOR inhibitor combination – major depressive disorder – Freedom Biosciences
  • Luvesilocin – serotonin 5-HT2A receptor agonist and psychedelic hallucinogen – postnatal depression – Reunion Neuroscience
  • Mebufotenin – non-selective serotonin receptor agonist and psychedelic hallucinogen – alcoholism, major depressive disorder – Beckley Psytech
  • Mebufotenin – non-selective serotonin receptor agonist and psychedelic hallucinogen – Alzheimer's disease, pain – Biomind Labs
  • Mebufotenin – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders – GH Research
  • Methylone – serotonin, norepinephrine, and dopamine releasing agent and entactogen – post-traumatic stress disorders, major depressive disorder, CNS disorders – Transcend Therapeutics
  • Midomafetamine – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen – alcoholism – Awakn Life Sciences
  • Midomafetamine/citalopram – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen followed by a selective serotonin reuptake inhibitor – post-traumatic stress disorder – Tactogen
  • MSP-1014 – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder – Mindset Pharma, Otsuka America Pharmaceutical
  • Non-racemic midomafetamine -MDMA, 20–30% – social anxiety in autism spectrum disorder – PharmAla Biotech
  • OSU-6162 – non-hallucinogenic serotonin 5-HT2A receptor partial agonist, dopamine D2 receptor partial agonist, and sigma σ1 receptor ligand – bipolar depression, chronic fatigue syndrome, depressive disorders, stroke, subarachnoid hemorrhage, Parkinson's disease – Carlsson Research AB, Pfizer
  • Psilocin – non-selective serotonin receptor agonist and psychedelic hallucinogen – adjustment disorder – Psyence BioMed
  • Psilocin – non-selective serotonin receptor agonist and psychedelic hallucinogen – generalized anxiety disorder – Diamond Therapeutics
  • Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders, anxiety disorders – Apex Laboratories
  • Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – Fragile X syndrome – restart Life Sciences
  • Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – mental disorders, major depressive disorder, anxiety disorders – Cybin
  • Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – post-traumatic stress disorder, anxiety disorders, depressive disorders, headache, substance-related disorders – Mydecine
  • Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – adjustment disorders, alcoholism, depressive disorders, anxiety disorders – Filament Health
  • Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – binge-eating disorder, fibromyalgia, irritable bowel syndrome, cancer, complex regional pain syndrome, pain – Tryp Therapeutics
  • Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – generalized anxiety disorder – Incannex
  • Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – demoralization syndrome – Reset Pharma
  • Psilocybin – alcoholism, obsessive–compulsive disorders, cluster headache, migraine – Ceruvia Lifesciences
  • Xenon – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – post-traumatic stress disorder, Alzheimer's disease, irritable bowel syndrome, Parkinson's disease, pervasive child development disorders, panic disorder – Nobilis Therapeutics
  • Zolunicant – α3β4 nicotinic acetylcholine receptor antagonist, other actions – leishmaniasis, opioid-related disorders, substance-related disorders – MindMed

    Phase 1/2

  • Dimethyltryptamine – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder – Small Pharma, Cybin
  • Dimethyltryptamine/harmine – non-selective serotonin receptor agonist, psychedelic hallucinogen, and monoamine oxidase inhibitor combination – generalized anxiety disorder – reconnect Labs
  • Ibogaine – various actions and hallucinogen – opioid-related disorders – ATAI Life Sciences/DemeRx
  • Mebufotenin – non-selective serotonin receptor agonist and psychedelic hallucinogen – generalized anxiety disorder – reconnect Labs
  • Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – substance-related disorders, neurological disorders, opioid-related disorders, psychiatric disorders, traumatic brain injury, cancer, anxiety disorders, bipolar disorders, depressive disorders, eating disorders, and additional unspecified conditions – Revive Therapeutics
  • Psilocybin infusion – non-selective serotonin receptor agonist and psychedelic hallucinogen – major depressive disorder – Eleusis, Beckley Psytech

    Phase 1

  • 2-Bromo-LSD – non-hallucinogenic serotonin 5-HT2A receptor agonist and other actions – cluster headache, migraine – Ceruvia Lifesciences
  • 5-Methoxy-2-aminoindane – serotonin releasing agent and entactogen – alcoholism, cocaine use disorder, metabolic syndrome, obesity – Clearmind Medicine
  • 5-MeO-MiPT – non-selective serotonin receptor agonist and psychedelic hallucinogen – undefined indication – Mindstate Design Labs
  • -Midomafetamine -MDMA; – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen – pervasive child development disorders/autism spectrum disorder – MindMed
  • -Midomafetamine – serotonin, norepinephrine, and dopamine releasing agent, weak serotonin 5-HT2A, 5-HT2B, 5-HT2C receptor agonist, entactogen, and weak psychedelic hallucinogen – post-traumatic stress disorder, social phobia – EmpathBio
  • BMND07 – non-selective serotonin receptor agonist, serotonergic hallucinogen, and other actions combination – major depressive disorder – Biomind Labs
  • Dimethyltryptamine – non-selective serotonin receptor agonist and psychedelic hallucinogen – stroke – Algernon Neuroscience
  • Dimethyltryptamine – non-selective serotonin receptor agonist and psychedelic hallucinogen – smoking withdrawal, alcoholism – Entheon Biomedical
  • Dimethyltryptamine – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders – ATAI Life Sciences, Viridia Life Sciences
  • Dimethyltryptamine/β-carboline – non-selective serotonin receptor agonist, psychedelic hallucinogen, and monoamine oxidase inhibitor combination – undisclosed – Psychae Therapeutics
  • ENX-205 – non-hallucinogenic serotonin 5-HT1A and 5-HT2A receptor agonist and dopamine D2 and D3 receptor antagonist – mood disorders, post-traumatic stress disorder – Engrail Therapeutics
  • Esketamine – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – alcoholism – Awakn Life Sciences
  • Ketamine oral – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – mood disorders – Neurocentrx Pharma
  • Ketanserin – serotonin 5-HT2A and α1-adrenergic receptor antagonist – hallucinogen antidote – MindMed
  • Lys-MDA – methylenedioxyamphetamine prodrug – unknown – MindMed, MiHKAL
  • Lys-MDMA – midomafetamine prodrug – unknown – MindMed, MiHKAL
  • Mebufotenin – non-selective serotonin receptor agonist and psychedelic hallucinogen – undisclosed – Usona Institute
  • Mebufotenin – non-selective serotonin receptor agonist and psychedelic hallucinogen – substance use disorders – Alvarius Pharmaceuticals
  • Mescaline – non-selective serotonin 5-HT2A receptor agonist and psychedelic hallucinogen – obesity, Parkinson's disease, inflammation – Biomind Labs
  • Mescaline – non-selective serotonin receptor agonist and psychedelic hallucinogen – alcoholism – Journey Colab
  • MSP-2020 – serotonin 5-HT2A receptor agonist and psychedelic hallucinogenic – mental disorders, major depressive disorder – Mindset Pharma, Otsuka America Pharmaceutical
  • Noribogaine – various actions – alcohol use disorder – DemeRx
  • Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – neuropsychiatric disorders, opioid use disorder, obsessive–compulsive disorder, premenstrual dysphoric disorder – MycoMedia Life Sciences
  • Psilocybin – non-selective serotonin receptor agonist and psychedelic hallucinogen – neurodegenerative disorders, metabolic disorders, psychiatric disorders – Arbormentis, Relmada Therapeutics
  • SNTX-2643 – atypical serotonin reuptake inhibitor – social anxiety disorder, anxiety disorders, depressive disorders – Sensorium Therapeutics
  • SPL028 – non-selective serotonin receptor agonist and psychedelic hallucinogen – depressive disorders – Cybin, Small Pharma
  • Zalsupindole – non-hallucinogenic serotonin 5-HT2A receptor agonist – CNS disorders, major depressive disorder – Delix Therapeutics